René Russo, Ph.D.CEO at Akrevia Therapeutics
René Russo, PharmD is currently Director of X4 Therapeutics following a recent completed merger of X4 with Arsanis, Inc where Dr. Russo served as President and Chief Executive Officer for 3 years. As CEO of Arsanis, Dr. Russo raised two private financing rounds and completed Arsanis’ successful IPO totaling more than $150M raised in just under 18 months. These funds enabled a global Phase 2 ICU trial of lead asset ASN100 for S. aureus in 17 countries and 65 centers as well as in-licensing of ASN500 for RSV. Prior to Arsanis, Dr. Russo spent over 11 years building key medical functions at Cubist Pharmaceuticals culminating in a $9.6B acquisition of the company by Merck. At Cubist, she contributed to the successful launch and commercialization of daptomycin (reaching over $1B in sales annually worldwide) and held various positions including Vice President, Global Medical Affairs where she led Global Medical Sciences, Clinical Microbiology, Health Economics/Outcomes Research and Field Medical Teams for a portfolio of anti-infective products. Dr. Russo played a key role in Cubist’s successful integration of two public companies, Optimer and Trius, in 2013. Prior to Cubist, Dr. Russo held several positions in R&D at Bristol-Myers Squibb contributing to the successful registration and commercialization of various anti-infectives including atazanavir and entecavir. Dr. Russo serves as a director for Life Science Cares, a rapidly growing nonprofit organization leveraging the collective impact of the Boston life sciences industry to address the cycle of poverty in the Boston area.